3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
9
Colorectal Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
Triple Negative Breast Neoplasms
1
Solid Cancer
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Astrocytoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Docetaxel
33
Prednisone
28
enzalutamide
19
Abiraterone Acetate
13
pembrolizumab
11
gallium 68 PSMA-11
9
Leuprolide
9
Radiotherapy
8
Pluvicto
8
Magnetic Resonance Spectroscopy
8
Nivolumab
7
Estramustine
7
abiraterone
6
Radiotherapy, Intensity-Modulated
6
Goserelin
6
Carboplatin
6
Biopsy
6
olaparib
5
cemiplimab
5
bicalutamide
5
Specimen Handling
5
Paclitaxel
5
Cyclophosphamide
5
temsirolimus
4
orteronel
4
darolutamide
4
cabazitaxel
4
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
4
Sirolimus
4
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled